LDS/Medical Tests/The BT-Reveal Early Pancreatic Cancer Test

The BT-Reveal Early Pancreatic Cancer Test

Pancreatic cancer is an aggressive malignancy and the third leading cause of cancer-related death in the United States. The annual incidence is approximately 12.9 per 100,000 persons, with a death rate of 11 per 100,000. Prognosis is poor: the five-year survival rate for metastatic disease is <3%, while early detection at stage I can increase survival to >40%.

Exocrine pancreatic cancers account for about 95% of cases, most commonly pancreatic ductal adenocarcinoma (PDAC). Less common are endocrine pancreatic neuroendocrine tumors. The majority of PDAC cases are driven by mutations in KRAS (mutated in ~90%), as well as CDKN2A, TP53, SMAD4, PALB2, BRCA1, BRCA2, STK11, PRSS1, and others.

The BT-Reveal™ Early Pancreatic Cancer Test is a noninvasive, blood-based liquid biopsy that uses next-generation sequencing (NGS) to detect methylation haplotypes in cell-free DNA (cfDNA) specific to pancreatic cancer. Test results are analyzed through a proprietary bioinformatics pipeline that interrogates 59 defined methylation haplotype regions associated with the development of pancreatic ductal adenocarcinoma. By focusing on DNA methylation signatures rather than germline variants, BT-Reveal enhances sensitivity for detecting tumor-derived cfDNA at very low concentrations.

Clinical validation (company white paper, 2024) demonstrated a sensitivity of approximately 83% for pancreatic cancer detection, including early-stage disease. The test is recommended for individuals at increased risk, such as those with a family history of pancreatic, breast, ovarian, prostate, or colon cancer; known hereditary cancer syndromes (e.g., Lynch syndrome, Peutz-Jeghers syndrome, Li-Fraumeni syndrome, familial atypical multiple mole melanoma [FAMMM], hereditary pancreatitis); or those with pancreatic cysts and inconclusive imaging findings (CT/MRI).

  • Early detection and interval screening of high-risk individuals for pancreatic cancer
  • Resolving inconclusive clinical imaging and improved surveillance of pancreatic cysts
  • May help inform therapeutic decisions by identifying patients who could benefit from earlier intervention

Positive or Abnormal Signal: cfDNA methylation pattern consistent with pancreatic cancer; follow-up imaging and clinical evaluation warranted.

Negative or No Signal: No methylation pattern detected. Does not completely exclude pancreatic cancer, especially in very early disease.

Not applicable

Next-generation sequencing (NGS) with methylation haplotype profiling of cfDNA.

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Amylase, Lipase, ALP, CA19-9, comprehensive metabolic panel, pancreatic biopsy, CA125, insulin, elastase, KRAS gene mutation analysis.
3 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login